» Articles » PMID: 29991895

Muscle Fat Infiltration Assessed by Total Psoas Density on Computed Tomography Predicts Mortality in Cirrhosis

Abstract

Background: Ongoing evidence suggests that sarcopenia adversely affects outcomes in cirrhosis. The aim of this study was to evaluate muscle fat infiltration as a component of sarcopenia and its prognostic value in this setting.

Methods: In 98 consecutive patients with cirrhosis, muscle density was measured during a computed tomography scan at the level of the fourth to fifth lumbar (L4) vertebrae. Univariate and multivariate Cox regression analysis was used to determine predictors of survival.

Results: Body mass index: median 26 (range 17-45.2); model for end-stage liver disease (MELD) score: median 11 (6-29); Child-Pugh (CP) score: median 7 (5-13), CP class: A=49 (50.5%), B=39 (40%), C=10 (9.5%); hepatocellular carcinoma: 14 (14.3%); follow up: median 45 (1-140) months. Median L4 total psoas area (TPA): 2022 (777-3806) mm; L4 average total psoas density (ATPD): 42.52 (21.26-59.8) HU. ATPD was significantly correlated with age (=-0.222, P=0.034), creatinine (=-0.41, P<0.001), albumin (=0.224, P=0.035), MELD score (=-0.218, P=0.034), and TPA (=0.415, P<0.001). Fifty-four patients (55.1%) died during follow up. In the multivariate analysis, higher CP score (hazard ratio [HR] 1.2, 95% confidence interval [CI] 1.04-1.41), advanced age (HR 1.038, 95%CI 1.006-1.07) and lower ATPD (HR 0.967, 95%CI 0.937-0.997) were predictors of mortality.

Conclusion: Muscle fat infiltration, as a result of sarcopenia, is a negative predictive factor of survival in cirrhosis, emphasizing the need for early identification of this subgroup of patients.

Citing Articles

Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis.

Wen Z, Tuo S, Ran Q, Yuan J, Li Y, Zhang Y Ann Med. 2025; 57(1):2473627.

PMID: 40038873 PMC: 11884100. DOI: 10.1080/07853890.2025.2473627.


Myopenia and body fat distribution in hospitalized ulcerative colitis patients: correlations with clinical characteristics and response to vedolizumab.

Wei W, Yan P, Zhang Y, Wang Q, Kang J, Liu P Front Nutr. 2025; 11:1411695.

PMID: 39758314 PMC: 11695233. DOI: 10.3389/fnut.2024.1411695.


Ultrasound Assessment of Sarcopenia in Alcoholic Liver Disease.

Enciu V, Ologeanu P, Fierbinteanu-Braticevici C Diagnostics (Basel). 2024; 14(17).

PMID: 39272674 PMC: 11394590. DOI: 10.3390/diagnostics14171891.


Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.

Xue H, Liu Y, Liu Y, Li H, Liang Q, Ma L PLoS One. 2024; 19(9):e0310017.

PMID: 39264966 PMC: 11392268. DOI: 10.1371/journal.pone.0310017.


Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.

Henin G, Loumaye A, Leclercq I, Lanthier N JHEP Rep. 2024; 6(2):100963.

PMID: 38322420 PMC: 10844870. DOI: 10.1016/j.jhepr.2023.100963.


References
1.
Montano-Loza A, Angulo P, Meza-Junco J, Prado C, Sawyer M, Beaumont C . Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016; 7(2):126-35. PMC: 4864157. DOI: 10.1002/jcsm.12039. View

2.
Montano-Loza A, Meza-Junco J, Prado C, Lieffers J, Baracos V, Bain V . Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011; 10(2):166-73, 173.e1. DOI: 10.1016/j.cgh.2011.08.028. View

3.
Tandon P, Ney M, Irwin I, Ma M, Gramlich L, Bain V . Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012; 18(10):1209-16. DOI: 10.1002/lt.23495. View

4.
Somsouk M, Kornfield R, Vittinghoff E, Inadomi J, Biggins S . Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl. 2011; 17(2):129-36. PMC: 3058247. DOI: 10.1002/lt.22218. View

5.
Heuman D, Abou-Assi S, Habib A, Williams L, Stravitz R, Sanyal A . Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004; 40(4):802-10. DOI: 10.1002/hep.20405. View